Aficamten is also currently being evaluated in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM; CEDAR-HCM, a clinical trial of aficamten in a pediatric ...
Background Hospitalisation with acute heart failure (AHF) carries a high risk of death, and those surviving to discharge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback